Genfit S.A. (OTCMKTS:GNFTF – Get Free Report)’s stock price dropped 14.3% on Friday . The company traded as low as $9.47 and last traded at $9.47. Approximately 392 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 538 shares. The stock had previously closed at $11.05.
Genfit Price Performance
The stock’s 50-day moving average price is $10.53 and its two-hundred day moving average price is $6.96.
About Genfit
Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.
In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.
Featured Articles
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
